ACCENDRA HEALTH INC/VA/
Close on Oct 19, 2026
- Market cap
- $16.89M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 29, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | Before market open | $613.20M | $-1.16 | $-0.19 |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 19, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 30, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 28, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 4, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 2, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 3, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 20, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 10, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | full year 2026 | $300.00M to $320.00M | Lowered |
| Revenue | full year 2026 | $2.45B to $2.55B | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Accendra Health filed with the SEC
Accendra Health Receives Continued Listing Standard Notice from NYSE;
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Updates on Capital Allocation and CEO Succession Timing Plans
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Adoption of Tax Asset Preservation Plan
Material agreement · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Second Quarter 2026 Continuing Operations Supplemental Slides August 10, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Health’s Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Accendra Health Announces Expiration and Final Results of Offers and Consent Solicitations
Other events · EX-99.1 to Form 8-K
Accendra Health Announces Early Results of Offers and Consent Solicitations
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Accendra Health Announces Offers and Consent Solicitations
Regulation FD disclosure · EX-99.1 to Form 8-K
SUBJECT TO EXECUTED NDA | CONFIDENTIAL Con | fid CO en NT tia AINS l |
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Accendra Health Reports First Quarter 2026 Financial Results and Announces Comprehensive Balance Sheet Optimization Transaction
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
First Quarter 2026 Continuing Operations
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Accendra Health Reports Fourth Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Fourth Quarter 2025 Continuing Operations
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Owens & Minor, Inc. Completes Sale of Products & Healthcare Services Business to Platinum Equity
Material agreement · Acquisition or disposition completed · New financial obligation · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Owens & Minor Announces Corporate Name Change to Accendra Health, Inc.
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Owens & Minor to Present at Upcoming Investor Conferences on December 2, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Bank of America Leveraged Finance
Regulation FD disclosure · EX-99.2 to Form 8-K
Owens & Minor Reports Third Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Third Quarter 2025 Continuing Operations
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Owens & Minor Announces Definitive Agreement to Divest Products & Healthcare Services Segment to Platinum Equity for
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Owens & Minor Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Operations Supplemental Earnings Slides August 11, 2025 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Owens & Minor and Rotech Healthcare Mutually Agree to Terminate Previously Announced Acquisition
Material agreement · Agreement terminated · Other events · EX-99.1 to Form 8-K
Owens & Minor Reports First Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
First Quarter 2025 Supplemental Earnings Slides
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Owens & Minor Announces Upsize and Pricing of Senior Secured Notes Offering
Regulation FD disclosure · EX-99.1 to Form 8-K
Owens & Minor Announces Launch of Senior Secured Notes Offering
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF RHI
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Risks Related to Rotechs Business and Operations
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Lender Presentation March 20, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Owens & Minor Reports Fourth Quarter & Full Year Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Fourth Quarter 2024 Supplemental Earnings Slides
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Owens & Minor Launches Financing for Rotech Acquisition and Provides Preliminary Fourth Quarter and Full Year 2024 Financial
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Proprietary to Owens & Minor, Inc. © 2025 Owens & Minor, Inc. Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Owens & Minor Reports Third Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Third Quarter 2024 Supplemental Earnings Slides
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Owens & Minor Reports Second Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Second Quarter 2024 Supplemental Earnings Slides
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K